NCT06804096

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)

Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP): A Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Dr. Md. Alimur Reza · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.

Conditions

• Pneumonia, Community-Acquired
• Bacterial Pneumonia

Interventions

Type	Name	Description
DRUG	Faropenem	Tab. Faropenem 200mg three times daily
DRUG	Co-amoxiclav	Tab. Co-Amoxiclav 625mg three times daily
DRUG	Clarithromycin 500 mg	Tab. Clarithromycin 500mg two times daily

Timeline

• Start date: 2025-02-20
• Primary completion: 2025-09-30
• Completion: 2025-12-01
• First posted: 2025-01-31
• Last updated: 2025-07-11

Locations

2 sites across 1 country: Bangladesh